Reliant Submits Response To FDA For Expanded Omacor Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Company seeks an indication for the omega-3 ester to treat high triglycerides as an adjunct to diet and statin therapy.
You may also be interested in...
GSK Gains Lovaza By Acquiring Reliant For $1.65 Billion
Addition of the triglyceride treatment will complement GSK’s Coreg CR physician base, company tells “The Pink Sheet” DAILY.
GSK Gains Lovaza By Acquiring Reliant For $1.65 Billion
Addition of the triglyceride treatment will complement GSK’s Coreg CR physician base, company tells “The Pink Sheet” DAILY.
Oscient To Market Antara Using 280-Person Primary Care Sales Force
Oscient acquired the U.S. rights to the fenofibrate drug from Reliant for $78 mil.